The SAHF's Medical and Scientific Advisory Council's Educational Symposium is a premier event that brings together medical professionals, researchers and other stakeholders from the field of haemophilia. This symposium has been instrumental in disseminating the latest advancements, research findings, and best practices related to haemophilia and bleeding disorders. By facilitating collaboration and knowledge sharing, it plays a vital role in enhancing the quality of care, treatment outcomes, and overall quality of life for individuals affected by these conditions.
Knowledge Exchange: The symposium aims to foster an environment of collaborative learning, allowing participants to share experiences, best practices, and cutting-edge research related to haemophilia and bleeding disorders. It provides a platform to bridge the gap between medical professionals and researchers ensuring that knowledge is effectively disseminated and implemented.
Education and Awareness: By offering a diverse range of educational sessions, the symposium aims to increase awareness and understanding of haemophilia and bleeding disorders among healthcare professionals and the wider community. It focuses on empowering individuals with the information necessary to make informed decisions regarding treatment, management, and overall well-being.
Networking and Support: The symposium serves as a crucial networking opportunity, facilitating connections between professionals and organizations. It encourages the establishment of support networks and collaborations.
SAHF MASAC Educational Symposium is made possible by generous sponsorships from these companies and organisations.
The South African Haemophilia Foundation is a non-profit organization that was established in 1970. The foundation is dedicated to advocating for the needs of the bleeding disorders community in South Africa. SAHF's mission is to ensure that people with bleeding disorders have access to appropriate and quality care, education, and support.
At Roche, finding innovative solutions for those affected by diseases of the blood is not only a priority, it’s in our blood. Our commitment extends beyond developing innovative therapies, to playing a wider role in improving patient’s quality of life. We are exploring the best ways to deliver innovations to patients as quickly and effectively as possible, which includes evolving and improving how our clinical trials are designed and how our therapies are administered. We are also looking at new ways to measure treatment success through the use of alternative clinical endpoints. We continue to invest in bringing innovative treatment options to people with diseases of the blood, as our teams strive to continually deliver transformational change for patients and the physicians who treat them.
